Corticotropin-releasing hormone, glutamate, and γ-aminobutyric acid in depression

Neuroscientist

Volumn 17, Issue 1, 2011, Pages 124-144

  Gao, Shang Feng ^a   Bao, Ai Min ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

aminobutyric acid; cerebrospinal fluid; corticotrophin releasing hormone; depression; glutamate; plasma

Indexed keywords

4 AMINOBUTYRIC ACID; CORTICOTROPIN RELEASING FACTOR; GLUTAMATE AMMONIA LIGASE; GLUTAMATE DECARBOXYLASE; GLUTAMATE RECEPTOR; GLUTAMATE TRANSPORTER; GLUTAMIC ACID;

ARTICLE; BIPOLAR DEPRESSION; CADAVER; CEREBROSPINAL FLUID; CLINICAL STUDY; DEPRESSION; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; PATHOGENESIS; PRIORITY JOURNAL; RAPHE NUCLEUS; REMISSION; SUPRAOPTIC NUCLEUS;

CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM;

EID: 79952149333     PISSN: 10738584     EISSN: 10894098     Source Type: Journal    
DOI: 10.1177/1073858410361780     Document Type: Article

References (196)

1. Altamura C., Maes M., Dai J., Meltzer HY 1995. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. (Pubitemid 26017262)
2. Altamura CA, Mauri MC, Ferrara A., Moro AR, D'Andrea G., Zamberlan F. 1993. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 150: 1731-3. (Pubitemid 23325960)
3. Arato M., Banki CM, Bissette G., Nemeroff CB 1989. Elevated CSF CRF in suicide victims. Biol Psychiatry 25: 355-9. (Pubitemid 19044261)
4. Arranz B., Cowburn R., Eriksson A., Vestling M., Marcusson J. 1992. Gamma-aminobutyric acid-B (GABAB) binding sites in postmortem suicide brains. Neuropsychobiology 26: 33-6.
5. Auer DP, Putz B., Kraft E., Lipinski B., Schill J., Holsboer F. 2000. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 47: 305-13. (Pubitemid 30109243)
6. Austin MC, Janosky JE, Murphy HA 2003. Increased corticotropin-releasing hormone immunoreactivity in monoamine-containing pontine nuclei of depressed suicide men. Mol Psychiatry 8: 324-32. (Pubitemid 36712926)
7. Banki CM, Bissette G., Arato M., O'Connor L., Nemeroff CB 1987. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 144: 873-7. (Pubitemid 17095723)
8. Banki CM, Karmacsi L., Bissette G., Nemeroff CB 1992. Cerebrospinal fluid neuropeptides in mood disorder and dementia. J Affect Disord 25: 39-45.
9. Bao AM, Hestiantoro A., Van Someren EJ, Swaab DF, Zhou JN 2005. Colocalization of corticotropin-releasing hormone and oestrogen receptor-alpha in the paraventricular nucleus of the hypothalamus in mood disorders. Brain 128: 1301-13. (Pubitemid 40826184)
10. Bao AM, Meynen G., Swaab DF 2008. The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev 57: 531-53. (Pubitemid 351381758)
11. Belanoff JK, Rothschild AJ, Cassidy F., DeBattista C., Baulieu EE, Schold C., and others. 2002. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 52: 386-92. (Pubitemid 35266729)
12. Benes FM, Todtenkopf MS, Logiotatos P., Williams M. 2000. Glutamate decarboxylase(65)-immunoreactive terminals in cingulate and prefrontal cortices of schizophrenic and bipolar brain. J Chem Neuroanat 20: 259-69. (Pubitemid 32162885)
13. Beneyto M., Kristiansen LV, Oni-Orisan A., McCullumsmith RE, Meador-Woodruff JH 2007. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 32: 1888-902. (Pubitemid 47258508)
14. Berman RM, Krystal JH, Charney DS 1996. Mechanism of action of antidepressants: monoamine hypotheses and beyond. In: Watson SJ, editor. Biology of schizophrenia and affective disease. Washington, DC: Palgrave. p 295-368.
15. Berman RM, Cappiello A., Anand A., Oren DA, Heninger GR, Charney DS, and others. 2000. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351-4. (Pubitemid 30109248)
16. Berrettini WH, Nurnberger JI Jr, Hare TA, Simmons-Alling S., Gershon ES 1986. CSF GABA in euthymic manic-depressive patients and controls. Biol Psychiatry 21: 844-6. (Pubitemid 16044010)
17. Berrettini WH, Nurnberger JI Jr, Hare TA, Simmons-Alling S., Gershon ES, Post RM 1983. Reduced plasma and CSF gamma-aminobutyric acid in affective illness: effect of lithium carbonate. Biol Psychiatry 18: 185-94. (Pubitemid 13139282)
18. Berrettini WH, Umberkoman-Wiita B., Nurnberger JI Jr, Vogel WH, Gershon ES, Post RM 1982. Platelet GABA-transaminase in affective illness. Psychiatry Res 7: 255-60. (Pubitemid 13240642)
19. Bhagwagar Z., Wylezinska M., Jezzard P., Evans J., Ashworth F., Sule A., and others. 2007. Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 61: 806-12. (Pubitemid 46330250)
20. Bhagwagar Z., Wylezinska M., Jezzard P., Evans J., Boorman E., PMM, and others. 2008. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 11: 255-60. (Pubitemid 351231824)
21. Bielau H., Steiner J., Mawrin C., Trubner K., Brisch R., Meyer-Lotz G., and others. 2007. Dysregulation of GABAergic neurotransmission in mood disorders: a postmortem study. Ann N Y Acad Sci 1096: 157-69. (Pubitemid 47092509)
22. Binder EB, Salyakina D., Lichtner P., Wochnik GM, Ising M., Putz B., and others. 2004. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36: 1319-25. (Pubitemid 39577942)
23. Bissette G., Klimek V., Pan J., Stockmeier C., Ordway G. 2003. Elevated concentrations of CRF in the locus coeruleus of depressed subjects. Neuropsychopharmacology 28: 1328-35. (Pubitemid 41070903)
24. Bjork JM, Moeller FG, Kramer GL, Kram M., Suris A., Rush AJ, and others. 2001. Plasma GABA levels correlate with aggressiveness in relatives of patients with unipolar depressive disorder. Psychiatry Res 101: 131-6. (Pubitemid 32245796)
25. Borden LA 1996. GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem Int 29: 335-56. (Pubitemid 26297678)
26. Boudaba C., Schrader LA, Tasker JG 1997. Physiological evidence for local excitatory synaptic circuits in the rat hypothalamus. J Neurophysiol 77: 3396-400. (Pubitemid 27290904)
27. Boudaba C., Szabo K., Tasker JG 1996. Physiological mapping of local inhibitory inputs to the hypothalamic paraventricular nucleus. J Neurosci 16: 7151-60. (Pubitemid 26382892)
28. Bowden CL 2005. A different depression: clinical distinctions between bipolar and unipolar depression. J Affect Disord 84: 117-25. (Pubitemid 40222492)
29. Buijs RM, Kalsbeek A. 2001. Hypothalamic integration of central and peripheral clocks. Nat Rev Neurosci 2: 521-6. (Pubitemid 33676587)
30. Carpenter LL, Schecter JM, Tyrka AR, Mello AF, Mello MF, Haggarty R., and others. 2006. Open-label tiagabine mono-therapy for major depressive disorder with anxiety. J Clin Psychiatry 67: 66-71. (Pubitemid 43213284)
31. Cartmell J., Schoepp DD 2000. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75: 889-907. (Pubitemid 30660476)
32. Caspi A., Sugden K., Moffitt TE, Taylor A., Craig IW, Harrington H., and others. 2003. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301: 386-9. (Pubitemid 36877077)
33. Castillo M., Kwock L., Courvoisie H., Hooper SR 2000. Proton MR spectroscopy in children with bipolar affective disorder: preliminary observations. AJNR Am J Neuroradiol 21: 832-8. (Pubitemid 30262828)
34. Catalan R., Gallart JM, Castellanos JM, Galard R. 1998. Plasma corticotropin-releasing factor in depressive disorders. Biol Psychiatry 44: 15-20. (Pubitemid 28305537)
35. Chaki S., Nakazato A., Kennis L., Nakamura M., Mackie C., Sugiura M., and others. 2004. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/ CRA0450. Eur J Pharmacol 485: 145-58. (Pubitemid 38134409)
36. Chamberlin E., Tsai GE 1998. A glutamatergic model of ECTinduced memory dysfunction. Harv Rev Psychiatry 5: 307-17. (Pubitemid 28182535)
37. Charlton BG, Leake A., Ferrier IN, Linton EA, Lowry PJ 1986. Corticotropin-releasing factor in plasma of depressed patients and controls. Lancet 1: 161-2. (Pubitemid 16183140)
38. Charney DS 1998. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 59 (Suppl 14). 11-4. (Pubitemid 28462383)
39. Chebib M. 2004. GABAC receptor ion channels. Clin Exp Pharmacol Physiol 31: 800-4.
40. Chebib M., Johnston GA 1999. The 'ABC' of GABA receptors: a brief review. Clin Exp Pharmacol Physiol 26: 937-40. (Pubitemid 29513638)
41. Cheetham SC, Crompton MR, Katona CL, Parker SJ, Horton RW 1988. Brain GABAA/benzodiazepine binding sites and glutamic acid decarboxylase activity in depressed suicide victims. Brain Res 460: 114-23.
42. Choudary PV, Molnar M., Evans SJ, Tomita H., Li JZ, Vawter MP, and others. 2005. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A 102: 15653-8. (Pubitemid 41528111)
43. Conti F., Minelli A., Melone M. 2004. GABA transporters in the mammalian cerebral cortex: localization, development and pathological implications. Brain Res Brain Res Rev 45: 196-212. (Pubitemid 38802871)
44. Coric V., Milanovic S., Wasylink S., Patel P., Malison R., Krystal JH 2003. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 167: 219-20. (Pubitemid 36628165)
45. Cowen PJ 2008. Serotonin and depression: pathophysiological mechanism or marketing myth ? Trends Pharmacol Sci 29: 433-6.
46. Cross JA, Cheetham SC, Crompton MR, Katona CL, Horton RW 1988. Brain GABAB binding sites in depressed suicide victims. Psychiatry Res 26: 119-29.
47. Cryan JF, Kaupmann K. 2005. Don't worry 'B' happy! A role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci 26: 36-43. (Pubitemid 40052708)
48. De Bellis MD, Gold PW, Geracioti TD Jr, Listwak SJ, Kling MA 1993. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 150: 656-7. (Pubitemid 23109940)
49. de Kloet ER, Fitzsimons CP, Datson NA, Meijer OC, Vreugdenhil E. 2009. Glucocorticoid signaling and stress-related limbic susceptibility pathway: About receptors, transcription machinery and microRNA. Brain Res 1293: 129-41.
50. de Kloet ER, Joels M., Holsboer F. 2005. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 6: 463-75. (Pubitemid 40769171)
51. Devanand DP, Shapira B., Petty F., Kramer G., Fitzsimons L., Lerer B., and others. 1995. Effects of electroconvulsive therapy on plasma GABA. Convuls Ther 11: 3-13.
52. Ducottet C., Griebel G., Belzung C. 2003. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog Neuropsychopharmacol Biol Psychiatry 27: 625-31. (Pubitemid 36645063)
53. Durkin MM, Smith KE, Borden LA, Weinshank RL, Branchek TA, Gustafson EL 1995. Localization of messenger RNAs encoding three GABA transporters in rat brain: an in situ hybridization study. Brain Res Mol Brain Res 33: 7-21.
54. Erecinska M., Silver IA 1990. Metabolism and role of glutamate in mammalian brain. Prog Neurobiol 35: 245-96. (Pubitemid 20304100)
55. Erlander MG, Tillakaratne NJ, Feldblum S., Patel N., Tobin AJ 1991. Two genes encode distinct glutamate decarboxylases. Neuron 7: 91-100.
56. Fatemi SH, Stary JM, Earle JA, Araghi-Niknam M., Eagan E. 2005. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr Res 72: 109-22. (Pubitemid 39550982)
57. Feldman S., Weidenfeld J. 1997. Hypothalamic mechanisms mediating glutamate effects on the hypothalamo-pituitary-adrenocortical axis. J Neural Transm 104: 633-42. (Pubitemid 27474677)
58. France RD, Urban B., Krishnan KR, Bissett G., Banki CM, Nemeroff C., and others. 1988. CSF corticotropin-releasing factor-like immunoactivity in chronic pain patients with and without major depression. Biol Psychiatry 23: 86-8. (Pubitemid 18008088)
59. Fremeau RT Jr, Voglmaier S., Seal RP, Edwards RH 2004. VGLUTs define subsets of excitatory neurons and suggest novel roles for glutamate. Trends Neurosci 27: 98-103. (Pubitemid 38167332)
60. Frye MA, Tsai GE, Huggins T., Coyle JT, Post RM 2007 a. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry 61: 162-6. (Pubitemid 46072777)
61. Frye MA, Watzl J., Banakar S., O'Neill J., Mintz J., Davanzo P., and others. 2007 b. Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacology 32: 2490-9. (Pubitemid 350126840)
62. Galard R., Catalan R., Castellanos JM, Gallart JM 2002. Plasma corticotropin-releasing factor in depressed patients before and after the dexamethasone suppression test. Biol Psychiatry 51: 463-8. (Pubitemid 34260966)
63. Garrick NA, Hill JL, Szele FG, Tomai TP, Gold PW, Murphy DL 1987. Corticotropin-releasing factor: a marked circadian rhythm in primate cerebrospinal fluid peaks in the evening and is inversely related to the cortisol circadian rhythm. Endocrinology 121: 1329-34. (Pubitemid 17155878)
64. Geracioti TD Jr, Loosen PT, Orth DN 1997. Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression. Biol Psychiatry 42: 165-74.
65. Geracioti TD Jr, Orth DN, Ekhator NN, Blumenkopf B., Loosen PT 1992. Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans. J Clin Endocrinol Metab 74: 1325-30.
66. Gerner RH, Cohen DJ, Fairbanks L., Anderson GM, Young JG, Scheinin M., and others. 1984 a. CSF neurochemistry of women with anorexia nervosa and normal women. Am J Psychiatry 141: 1441-4. (Pubitemid 14023947)
67. Gerner RH, Fairbanks L., Anderson GM, Young JG, Scheinin M., Linnoila M., and others. 1984 b. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am J Psychiatry 141: 1533-40. (Pubitemid 15219750)
68. Gerner RH, Hare TA 1981. CSF GABA in normal subjects and patients with depression, schizophrenia, mania, and anorexia nervosa. Am J Psychiatry 138: 1098-101. (Pubitemid 11012815)
69. Goddard AW, Narayan M., Woods SW, Germine M., Kramer GL, Davis LL, and others. 1996. Plasma levels of gamma-aminobutyric acid and panic disorder. Psychiatry Res 63: 223-5. (Pubitemid 26276614)
70. Gold BI, Bowers MB Jr, Roth RH, Sweeney DW 1980. GABA levels in CSF of patients with psychiatric disorders. Am J Psychiatry 137: 362-4. (Pubitemid 10155047)
71. Gorman JM 2003. New molecular targets for antianxiety interventions. J Clin Psychiatry 64 (Suppl 3). 28-35. (Pubitemid 36389869)
72. Gos T., Gunther K., Bielau H., Dobrowolny H., Mawrin C., Trubner K., and others. 2008. Suicide and depression in the quantitative analysis of glutamic acid decarboxylase-immunorective neuropil. J Affect Disord. 2009 ; 113 (1-2). 45-55.
73. Grammatopoulos DK, Chrousos GP 2002. Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab 13: 436-44. (Pubitemid 36733938)
74. Grove J., Schechter PJ, Hanke NF, de Smet Y., Agid Y., Tell G., and others. 1982. Concentration gradients of free and total gamma-aminobutyric acid and homocarnosine in human CSF: comparison of suboccipital and lumbar sampling. J Neurochem 39: 1618-22. (Pubitemid 13184138)
75. Guidotti A., Auta J., Davis JM, Di-Giorgi-Gerevini V., Dwivedi Y., Grayson DR, and others. 2000. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 57: 1061-9.
76. Hasler G., van der Veen JW, Tumonis T., Meyers N., Shen J., Drevets WC 2007. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 64: 193-200. (Pubitemid 46220776)
77. Heckers S., Stone D., Walsh J., Shick J., Koul P., Benes FM 2002. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry 59: 521-9. (Pubitemid 34602934)
78. Herman JP, Figueiredo H., Mueller NK, Ulrich-Lai Y., Ostrander MM, Choi DC, and others. 2003. Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front Neuroendocrinol 24: 151-80. (Pubitemid 37336539)
79. Herman JP, Mueller NK, Figueiredo H. 2004. Role of GABA and glutamate circuitry in hypothalamo-pituitary-adrenocortical stress integration. Ann N Y Acad Sci 1018: 35-45. (Pubitemid 38951388)
80. Herzog E., Gilchrist J., Gras C., Muzerelle A., Ravassard P., Giros B., and others. 2004. Localization of VGLUT3, the vesicular glutamate transporter type 3, in the rat brain. Neuroscience 123: 983-1002. (Pubitemid 38130107)
81. Heuser I., Bissette G., Dettling M., Schweiger U., Gotthardt U., Schmider J., and others. 1998. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depress Anxiety 8: 71-9. (Pubitemid 28458051)
82. Hirschfeld RM 2000. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 61 (Suppl 6). 4-6. (Pubitemid 30217404)
83. Hoekstra R., Fekkes D., Loonen AJ, Pepplinkhuizen L., Tuinier S., Verhoeven WM 2006. Bipolar mania and plasma amino acids: increased levels of glycine. Eur Neuropsychopharmacol 16: 71-7. (Pubitemid 43005097)
84. Holden C. 2000. Mental health. Global survey examines impact of depression. Science 288: 39-40. (Pubitemid 30203016)
85. Holemans S., De Paermentier F., Horton RW, Crompton MR, Katona CL, Maloteaux JM 1993. NMDA glutamatergic receptors, labelled with [3H]MK-801, in brain samples from drug-free depressed suicides. Brain Res 616: 138-43. (Pubitemid 23200040)
86. Holsboer F. 2001. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord 62: 77-91. (Pubitemid 32126613)
87. Holsboer F., Barden N. 1996. Antidepressants and hypothalamic-pituitary- adrenocortical regulation. Endocr Rev 17: 187-205. (Pubitemid 26119958)
88. Holsboer F., Ising M. 2008. Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583: 350-7.
89. Jones MT, Gillham B., Altaher AR, Nicholson SA, Campbell EA, Watts SM, and others. 1984. Clinical and experimental studies on the role of GABA in the regulation of ACTH secretion: a review. Psychoneuroendocrinology 9: 107-23. (Pubitemid 14089181)
90. Kalin NH, Shelton SE, Barksdale CM, Brownfield MS 1987. A diurnal rhythm in cerebrospinal fluid corticotrophin-releasing hormone different from the rhythm of pituitary-adrenal activity. Brain Res 426: 385-91. (Pubitemid 17155624)
91. Karolewicz B., Stockmeier CA, Ordway GA 2005. Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression. Neuropsychopharmacology 30: 1557-67. (Pubitemid 41153128)
92. Kasa K., Otsuki S., Yamamoto M., Sato M., Kuroda H., Ogawa N. 1982. Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. Biol Psychiatry 17: 877-83. (Pubitemid 12046064)
93. Kasckow JW, Baker D., Geracioti TD Jr. 2001. Corticotropin-releasing hormone in depression and post-traumatic stress disorder. Peptides 22: 845-51. (Pubitemid 32397737)
94. Kling MA, Geracioti TD, Licinio J., Michelson D., Oldfield EH, Gold PW 1994. Effects of electroconvulsive therapy on the CRH-ACTH-cortisol system in melancholic depression: preliminary findings. Psychopharmacol Bull 30: 489-94.
95. Kling MA, Roy A., Doran AR, Calabrese JR, Rubinow DR, Whitfield HJ Jr, and others. 1991. Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing's disease and major depression: potential clinical implications. J Clin Endocrinol Metab 72: 260-71. (Pubitemid 21921686)
96. Korpi ER, Sinkkonen ST 2006. GABA(A) receptor subtypes as targets for neuropsychiatric drug development. Pharmacol Ther 109: 12-32. (Pubitemid 41740812)
97. Kudoh A., Takahira Y., Katagai H., Takazawa T. 2002. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 95: 114-8. (Pubitemid 34705563)
98. Lai CT, Tanay VA, Charrois GJ, Baker GB, Bateson AN 1998. Effects of phenelzine and imipramine on the steady-state levels of mRNAs that encode glutamic acid decarboxylase (GAD67 and GAD65), the GABA transporter GAT-1 and GABA transaminase in rat cortex. Naunyn Schmiedebergs Arch Pharmacol 357: 32-8. (Pubitemid 28085118)
99. Law AJ, Deakin JF 2001. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 12: 2971-4. (Pubitemid 32882018)
100. Leonard BE 2007. Psychopathology of depression. Drugs Today (Barc) 43: 705-16. (Pubitemid 350220794)
101. Lesch KP 2004. Gene-environment interaction and the genetics of depression. J Psychiatry Neurosci 29: 174-84. (Pubitemid 38829854)
102. Liberzon I., Krstov M., Young EA 1997. Stress-restress: effects on ACTH and fast feedback. Psychoneuroendocrinology 22: 443-53. (Pubitemid 27431506)
103. Liu GX, Cai GQ, Cai YQ, Sheng ZJ, Jiang J., Mei Z., and others. 2007. Reduced anxiety and depression-like behaviors in mice lacking GABA transporter subtype 1. Neuropsychopharmacology 32: 1531-9. (Pubitemid 46920158)
104. Loscher W. 1982. Relationship between GABA concentrations in cerebrospinal fluid and seizure excitability. J Neurochem 38: 293-5.
105. Maes M., Verkerk R., Vandoolaeghe E., Lin A., Scharpe S. 1998. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 97: 302-8. (Pubitemid 28179268)
106. Mauri MC, Ferrara A., Boscati L., Bravin S., Zamberlan F., Alecci M., and others. 1998. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 37: 124-9. (Pubitemid 28171767)
107. McCullumsmith RE, Kristiansen LV, Beneyto M., Scarr E., Dean B., Meador-Woodruff JH 2007. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 1127: 108-18. (Pubitemid 44854837)
108. McCullumsmith RE, Meador-Woodruff JH 2002. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology 26: 368-75. (Pubitemid 34159214)
109. McEntee WJ, Crook TH 1993. Glutamate: its role in learning, memory, and the aging brain. Psychopharmacology (Berl) 111: 391-401. (Pubitemid 23205661)
110. McKenna KF, McManus DJ, Baker GB, Coutts RT 1994. Chronic administration of the antidepressant phenelzine and its N-acetyl analogue: effects on GABAergic function. J Neural Transm Suppl 41: 115-22. (Pubitemid 24215681)
111. Merali Z., Du L., Hrdina P., Palkovits M., Faludi G., Poulter MO, and others. 2004. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 24: 1478-85. (Pubitemid 38223000)
112. Merali Z., Kent P., Du L., Hrdina P., Palkovits M., Faludi G., and others. 2006. Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biol Psychiatry 59: 594-602. (Pubitemid 43357953)
113. Michael N., Erfurth A., Ohrmann P., Arolt V., Heindel W., Pfleiderer B. 2003 a. Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychol Med 33: 1277-84. (Pubitemid 37265215)
114. Michael N., Erfurth A., Ohrmann P., Arolt V., Heindel W., Pfleiderer B. 2003 b. Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression. Neuropsychopharmacology 28: 720-5.
115. Miller G. 2005. Neuroscience. The dark side of glia. Science 308: 778-81.
116. Mirza Y., Tang J., Russell A., Banerjee SP, Bhandari R., Ivey J., and others. 2004. Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression. J Am Acad Child Adolesc Psychiatry 43: 341-8. (Pubitemid 41615014)
117. Mitani H., Shirayama Y., Yamada T., Maeda K., Ashby CR Jr, Kawahara R. 2006. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 30: 1155-8. (Pubitemid 43928219)
118. Molchan SE, Hill JL, Martinez RA, Lawlor BA, Mellow AM, Rubinow DR, and others. 1993. CSF somatostatin in Alzheimer's disease and major depression: relationship to hypothalamic-pituitary-adrenal axis and clinical measures. Psychoneuroendocrinology 18: 509-19. (Pubitemid 23289036)
119. Moutsimilli L., Farley S., Dumas S., El Mestikawy S., Giros B., Tzavara ET 2005. Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology 49: 890-900. (Pubitemid 41483895)
120. Murray CJ, Lopez AD 1996. Evidence-based health policy- lessons from the Global Burden of Disease Study. Science 274: 740-3. (Pubitemid 26398244)
121. Neigh GN, Nemeroff CB 2006. Reduced glucocorticoid receptors: consequence or cause of depression ? Trends Endocrinol Metab 17: 124-5. (Pubitemid 44308199)
122. Nemeroff CB, Bissette G., Akil H., Fink M. 1991. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin. Br J Psychiatry 158: 59-63.
123. Nemeroff CB, Owens MJ, Bissette G., Andorn AC, Stanley M. 1988. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 45: 577-9.
124. Nemeroff CB, Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., and others. 1984. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226: 1342-4. (Pubitemid 15215592)
125. Nestler EJ, Barrot M., DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM 2002. Neurobiology of depression. Neuron 34: 13-25. (Pubitemid 34270695)
126. Nikisch G., Agren H., Eap CB, Czernik A., Baumann P., Mathe AA 2005. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol 8: 403-10. (Pubitemid 41002494)
127. Nikisch G., Mathe AA 2008. CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy. Eur Psychiatry 23: 356-9.
128. Nowak G., Ordway GA, Paul IA 1995. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 675: 157-64.
129. Nowak G., Szewczyk B., Sadlik K., Piekoszewski W., Trela F., Florek E., and others. 2003. Reduced potency of zinc to interact with NMDA receptors in hippocampal tissue of suicide victims. Pol J Pharmacol 55: 455-9. (Pubitemid 36975214)
130. Ongur D., Drevets WC, Price JL 1998. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 95: 13290-5. (Pubitemid 28509564)
131. Overstreet DH, Griebel G. 2004. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol 497: 49-53. (Pubitemid 39092427)
132. Palmio J., Huuhka M., Saransaari P., Oja SS, Peltola J., Leinonen E., and others. 2005. Changes in plasma amino acids after electroconvulsive therapy of depressed patients. Psychiatry Res 137: 183-90. (Pubitemid 41712775)
133. Pandey GN, Conley RR, Pandey SC, Goel S., Roberts RC, Tamminga CA, and others. 1997. Benzodiazepine receptors in the post-mortem brain of suicide victims and schizophrenic subjects. Psychiatry Res 71: 137-49. (Pubitemid 27346804)
134. Paredes RG, Agmo A. 1992. GABA and behavior: the role of receptor subtypes. Neurosci Biobehav Rev 16: 145-70.
135. Pariante CM 2006. The glucocorticoid receptor: part of the solution or part of the problem ? J Psychopharmacol 20: 79-84. (Pubitemid 44576663)
136. Pariante CM, Lightman SL 2008. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 31: 464-8.
137. Perry EK, Gibson PH, Blessed G., Perry RH, Tomlinson BE 1977. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 34: 247-65. (Pubitemid 8188071)
138. Petroff OA 2002. GABA and glutamate in the human brain. Neuroscientist 8: 562-73. (Pubitemid 35379451)
139. Petty F. 1994. Plasma concentrations of gamma-aminobutyric acid (GABA) and mood disorders: a blood test for manic depressive disease ? Clin Chem 40: 296-302.
140. Petty F. 1995. GABA and mood disorders: a brief review and hypothesis. J Affect Disord 34: 275-81.
141. Petty F., Fulton M., Kramer GL, Kram M., Davis LL, Rush AJ 1999. Evidence for the segregation of a major gene for human plasma GABA levels. Mol Psychiatry 4: 587-9.
142. Petty F., Kramer G. 1992. Stability of plasma gamma-aminobutyric acid with time in healthy controls. Biol Psychiatry 31: 743-5.
143. Petty F., Kramer GL, Dunnam D., Rush AJ 1990. Plasma GABA in mood disorders. Psychopharmacol Bull 26: 157-61. (Pubitemid 20291868)
144. Petty F., Kramer GL, Fulton M., Davis L., Rush AJ 1995. Stability of plasma GABA at four-year follow-up in patients with primary unipolar depression. Biol Psychiatry 37: 806-10.
145. Petty F., Kramer GL, Fulton M., Moeller FG, Rush AJ 1993 a. Low plasma GABA is a trait-like marker for bipolar illness. Neuropsychopharmacology 9: 125-32. (Pubitemid 23275838)
146. Petty F., Kramer GL, Gullion CM, Rush AJ 1992. Low plasma gamma-aminobutyric acid levels in male patients with depression. Biol Psychiatry 32: 354-63.
147. Petty F., Kramer GL, Hendrickse W. 1993 b. GABA and depression. In: Mann JJ, Kupfer DJ, editors. Biology of depressive disorders, part a: a systems perspective. New York: Plenum Press. p 79-108.
148. Petty F., Rush AJ, Davis JM, Calabrese JR, Kimmel SE, Kramer GL, and others. 1996. Plasma GABA predicts acute response to divalproex in mania. Biol Psychiatry 39: 278-84. (Pubitemid 26084379)
149. Petty F., Schlesser MA 1981. Plasma GABA in affective illness. A preliminary investigation. J Affect Disord 3: 339-43. (Pubitemid 12248167)
150. Petty F., Sherman AD 1984. Plasma GABA levels in psychiatric illness. J Affect Disord 6: 131-8. (Pubitemid 14135649)
151. Petty F., Steinberg J., Kramer GL, Fulton M., Moeller FG 1993 c. Desipramine does not alter plasma GABA in patients with major depression. J Affect Disord 29: 53-6. (Pubitemid 23272989)
152. Pfleiderer B., Michael N., Erfurth A., Ohrmann P., Hohmann U., Wolgast M., and others. 2003. Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res 122: 185-92. (Pubitemid 36412193)
153. Pitts AF, Samuelson SD, Meller WH, Bissette G., Nemeroff CB, Kathol RG 1995. Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls. Biol Psychiatry 38: 330-5.
154. Price RB, Shungu DC, Mao X., Nestadt P., Kelly C., Collins KA, and others. 2009. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry 65: 792-800.
155. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF 1994. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60: 436-44. (Pubitemid 24284827)
156. Raadsheer FC, van Heerikhuize JJ, Lucassen PJ, Hoogendijk WJ, Tilders FJ, Swaab DF 1995. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am J Psychiatry 152: 1372-6.
157. Rajkowska G., Halaris A., Selemon LD 2001. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 49: 741-52. (Pubitemid 32452295)
158. Rajkowska G., Miguel-Hidalgo JJ, Wei J., Dilley G., Pittman SD, Meltzer HY, and others. 1999. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45: 1085-98. (Pubitemid 29236550)
159. Rivier C., Vale W. 1983. Interaction of corticotropin-releasing factor and arginine vasopressin on adrenocorticotropin secretion in vivo. Endocrinology 113: 939-42. (Pubitemid 13051934)
160. Rosenberg DR, Macmaster FP, Mirza Y., Smith JM, Easter PC, Banerjee SP, and others. 2005. Reduced anterior cingulate glutamate in pediatric major depression: a magnetic resonance spectroscopy study. Biol Psychiatry 58: 700-4. (Pubitemid 41547237)
161. Rothman DL, Petroff OA, Behar KL, Mattson RH 1993. Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci U S A 90: 5662-6. (Pubitemid 23176221)
162. Roy-Byrne PP, Cowley DS, Hommer D., Greenblatt DJ, Kramer GL, Petty F. 1992. Effect of acute and chronic benzodiazepines on plasma GABA in anxious patients and controls. Psychopharmacology (Berl) 109: 153-6.
163. Roy A., Dejong J., Ferraro T. 1991. CSF GABA in depressed patients and normal controls. Psychol Med 21: 613-8.
164. Roy A., Pickar D., Paul S., Doran A., Chrousos GP, Gold PW 1987. CSF corticotropin-releasing hormone in depressed patients and normal control subjects. Am J Psychiatry 144: 641-5. (Pubitemid 17067342)
165. Ruhe HG, Mason NS, Schene AH 2007. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 12: 331-59. (Pubitemid 46496835)
166. Sanacora G., Gueorguieva R., Epperson CN, Wu YT, Appel M., Rothman DL, and others. 2004. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61: 705-13. (Pubitemid 38890805)
167. Sanacora G., Mason GF, Rothman DL, Behar KL, Hyder F., Petroff OA, and others. 1999. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 56: 1043-7. (Pubitemid 29526389)
168. Sanacora G., Saricicek A. 2007. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets 6: 127-40. (Pubitemid 46681773)
169. Scarr E., Pavey G., Sundram S., MacKinnon A., Dean B. 2003. Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disord 5: 257-64. (Pubitemid 37009889)
170. Scott LV, Dinan TG 1998. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sci 62: 1985-98. (Pubitemid 28239711)
171. Seal RP, Amara SG 1999. Excitatory amino acid transporters: a family in flux. Annu Rev Pharmacol Toxicol 39: 431-56. (Pubitemid 29222566)
172. Shigeri Y., Seal RP, Shimamoto K. 2004. Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev 45: 250-65. (Pubitemid 38802874)
173. Stocks GM, Cheetham SC, Crompton MR, Katona CL, Horton RW 1990. Benzodiazepine binding sites in amygdala and hippocampus of depressed suicide victims. J Affect Disord 18: 11-5. (Pubitemid 20004848)
174. Stryjer R., Strous RD, Shaked G., Bar F., Feldman B., Kotler M., and others. 2003. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol 18: 93-6. (Pubitemid 36343978)
175. Sundman-Eriksson I., Allard P. 2002. [(3)H]Tiagabine binding to GABA transporter-1 (GAT-1) in suicidal depression. J Affect Disord 71: 29-33.
176. Sundman I., Allard P., Eriksson A., Marcusson J. 1997. GABA uptake sites in frontal cortex from suicide victims and in aging. Neuropsychobiology 35: 11-5. (Pubitemid 27037717)
177. Swaab DF, Bao AM, Lucassen PJ 2005. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 4: 141-94. (Pubitemid 41114861)
178. Swaab DF, Fliers E., Hoogendijk WJ, Veltman DJ, Zhou JN 2000. Interaction of prefrontal cortical and hypothalamic systems in the pathogenesis of depression. Prog Brain Res 126: 369-96. (Pubitemid 35461301)
179. Taylor M., Murphy SE, Selvaraj S., Wylezinkska M., Jezzard P., Cowen PJ, and others. 2008. Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy. J Psychopharmacol 22: 473-6.
180. Tordera RM, Pei Q., Sharp T. 2005. Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment. J Neurochem 94: 875-83. (Pubitemid 41170576)
181. Toro C., Deakin JF 2005. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr Res 80: 323-30. (Pubitemid 41713658)
182. Toro CT, Hallak JE, Dunham JS, Deakin JF 2006. Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. Neurosci Lett 404: 276-81. (Pubitemid 44108429)
183. van Rossum EF, Binder EB, Majer M., Koper JW, Ising M., Modell S., and others. 2006. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry 59: 681-8.
184. Varoqui H., Schafer MK, Zhu H., Weihe E., Erickson JD 2002. Identification of the differentiation-associated Na+/PI transporter as a novel vesicular glutamate transporter expressed in a distinct set of glutamatergic synapses. J Neurosci 22: 142-55. (Pubitemid 34033492)
185. Veith RC, Lewis N., Langohr JI, Murburg MM, Ashleigh EA, Castillo S., and others. 1993. Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Psychiatry Res 46: 1-8. (Pubitemid 23066266)
186. Wang SS, Kamphuis W., Huitinga I., Zhou JN, Swaab DF 2008. Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances. Mol Psychiatry 13: 786-99, 41.
187. Webster MJ, Knable MB, O'Grady J., Orthmann J., Weickert CS 2002. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry 7: 985-94, 924. (Pubitemid 35333054)
188. Westrin A., Ekman R., Traskman-Bendz L. 1999. Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt. Eur Neuropsychopharmacol 9: 205-11. (Pubitemid 29114925)
189. Widerlov E., Bissette G., Nemeroff CB 1988. Monoamine metabolites, corticotropin releasing factor and somatostatin as CSF markers in depressed patients. J Affect Disord 14: 99-107. (Pubitemid 18060246)
190. Wolkowitz OM, Reus VI 1999. Treatment of depression with antiglucocorticoid drugs. Psychosom Med 61: 698-711. (Pubitemid 29455090)
191. Woo TU, Walsh JP, Benes FM 2004. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 61: 649-57. (Pubitemid 38890797)
192. Zarate CA Jr, Payne JL, Quiroz J., Sporn J., Denicoff KK, Luckenbaugh D., and others. 2004. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 161: 171-4. (Pubitemid 38419327)
193. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R., Luckenbaugh DA, and others. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-64. (Pubitemid 44188478)
194. Zhou JN, Riemersma RF, Unmehopa UA, Hoogendijk WJ, van Heerikhuize JJ, Hofman MA, and others. 2001. Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry 58: 655-62. (Pubitemid 32640861)
195. Zhu H., Karolewicz B., Nail E., Stockmeier CA, Szebeni K., Ordway GA 2006. Normal [3H]flunitrazepam binding to GABAA receptors in the locus coeruleus in major depression and suicide. Brain Res 1125: 138-46. (Pubitemid 44838547)
196. Zimmer R., Teelken AW, Meier KD, Ackenheil M., Zander KJ 1980. Preliminary studies on CSF gamma-aminobutyric acid levels in psychiatric patients before and during treatment with different psychotropic drugs. Prog Neuropsychopharmacol 4: 613-20. (Pubitemid 11189495)